Research Library

open-access-imgOpen AccessKaempferol regulates apoptosis and migration of neural stem cells to attenuate cerebral infarction by O ‐GlcNAcylation of β-catenin
Author(s)
Zhang Song,
Jiao Honglei
Publication year2024
Publication title
open life sciences
Resource typeJournals
PublisherDe Gruyter
Ischemic stroke remains a major cause of disability and death. Kaempferol (Kae) is a neuroprotective flavonoid compound. Thus, this study aimed to explore the impact of Kae on cerebral infarction. We generated the middle cerebral artery occlusion (MCAO) mouse model to study the effects of Kae on infarction volume and neurological function. The oxygen and glucose deprivation (OGD)/reoxygenation (R) model of neural stem cells (NSCs) was established to study the effects of Kae on cell viability, migration, and apoptosis. Cell processes were assessed by cell counting kit-8, Transwell assay, flow cytometry, and TUNEL analysis. The molecular mechanism was assessed using the Western blot. The results indicated that Kae attenuated MCAO-induced cerebral infarction and neurological injury. Besides, Kae promoted cell viability and migration and inhibited apoptosis of OGD/R-treated NSCs. Moreover, OGD/R suppressed total O ‐GlcNAcylation level and O ‐GlcNAcylation of β-catenin, thereby suppressing the Wnt/β-catenin pathway, whereas Kae reversed the suppression. Inactivation of the Wnt/β-catenin pathway abrogated the biological functions of NSCs mediated by Kae. In conclusion, Kae suppressed cerebral infarction by facilitating NSC viability, migration, and inhibiting apoptosis. Mechanically, Kae promoted O ‐GlcNAcylation of β-catenin to activate the Wnt/β-catenin pathway. Kae may have a lessening effect on ischemic stroke.
Keyword(s)kaempferol, Wnt/β-catenin pathway, O ‐GlcNAcylation, MCAO, OGD/R, apoptosis
Language(s)English
SCImago Journal Rank0.238
H-Index34
eISSN2391-5412
DOI10.1515/biol-2022-0829

Seeing content that should not be on Zendy? Contact us.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here